Company Filing History:
Years Active: 2011
Title: Takuo Osawa: Innovator in Chondroitin Synthase Research
Introduction
Takuo Osawa is a notable inventor based in Fukuoka, Japan, with a focus on biochemistry and molecular biology. He holds two patents, showcasing his expertise in the field and contributing to advancements in chondroitin synthase research.
Latest Patents
Osawa's recent patents include the significant invention of a modified chondroitin synthase polypeptide and its crystalline forms. This innovation comprises a polypeptide that either consists of the amino acid sequence of SEQ ID NO:2 or includes deletions, substitutions, or additions of one or more amino acid residues while maintaining chondroitin synthase activity. Additionally, he developed a method for producing this polypeptide, which involves expressing a nucleic acid to produce the polypeptide and subsequently collecting it. His inventions also describe a crystal form of the polypeptide, which may be categorized as monoclinic or tetragonal.
Career Highlights
Osawa is affiliated with Seikagaku Corporation, a prominent company in the field of biopharmaceuticals. His work has operationalized critical research components that could lead to breakthroughs in therapeutic applications related to chondroitin, a significant molecule in maintaining cartilage health.
Collaborations
During his career, Osawa has worked alongside esteemed colleagues such as Yoshimitsu Kakuta and Nobuo Sugiura. These collaborations have likely fostered an environment of innovation, enabling the integration of diverse expertise into their collective research endeavors.
Conclusion
Takuo Osawa exemplifies the spirit of innovation within the scientific community. Through his two patents and ongoing research at Seikagaku Corporation, he continues to contribute valuable advancements to the understanding and utilization of chondroitin synthase, highlighting the importance of collaborative efforts in driving scientific progress.